-
公开(公告)号：CH694053A5
公开(公告)日：2004-06-30
申请号：CH155099
申请日：1999-08-24
Applicant: HOFFMANN LA ROCHE
Inventor： ADAM GEO , HUGUENIN-VIRCHAUX PHILIPPE NIC , MUTEL VINCENT
IPC: A61K31/00 , A61K31/196 , A61P25/00 , A61P25/18 , C07C227/16 , C07C227/32 , C07C229/50 , C07C247/14 , C07C227/04
-
公开(公告)号：DE60005386T2
公开(公告)日：2004-06-24
申请号：DE60005386
申请日：2000-09-29
Applicant: HOFFMANN LA ROCHE
Inventor： ADAM GEO , ALANINE ALEXANDER , GOETSCHI ERWIN , MUTEL VINCENT , WOLTERING JOHANNES
IPC: A61K31/55 , A61K31/551 , A61K31/5513 , A61P1/08 , A61P3/08 , A61P9/00 , A61P9/10 , A61P13/00 , A61P21/02 , A61P25/00 , A61P25/04 , A61P25/06 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/34 , A61P25/36 , A61P27/02 , A61P43/00 , C07D243/12 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/04 , C07D405/06 , C07D409/04 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D417/10 , C07D417/14 , C07D491/056 , C07D491/113 , C07F7/10
Abstract: The present invention relates to compounds of with a base structure of formula 1The compounds of formula I are shown to have activity as metabotropic glutamate receptor antagonists.
-
公开(公告)号：CZ20033003A3
公开(公告)日：2004-05-12
申请号：CZ20033003
申请日：2002-04-02
Applicant: HOFFMANN LA ROCHE
Inventor： ADAM GEO , GOETSCHI ERWIN , MUTEL VINCENT , WICHMANN JUERGEN , WOLTERING THOMAS JOHANNES
IPC: C07D243/12 , A61K31/551 , A61K31/5513 , A61P25/00 , A61P25/18 , A61P25/28 , A61P43/00 , C07D401/04 , C07D403/04 , C07D403/10 , C07D403/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14 , A61K31/4427 , A61K31/4025
Abstract: This invention is a dihydro-benzo[b][1,4]diazepin-2-one derivative of the formulawherein R1, R2, R3, X and Y are as defined in the specification. The invention includes pharmaceutical compositions containing these compounds, a process for their preparation, their use in preparation of pharmaceutical compositions and administration of an effective amount of the compounds for the treatment or prevention of acute and/or chronic neurological disorders to a patient in need of such treatment.
-
公开(公告)号：AT261945T
公开(公告)日：2004-04-15
申请号：AT00971302
申请日：2000-09-29
Applicant: HOFFMANN LA ROCHE
Inventor： ADAM GEO , ALANINE ALEXANDER , GOETSCHI ERWIN , MUTEL VINCENT , WOLTERING THOMAS JOHANNES
IPC: A61K31/55 , A61K31/551 , A61K31/5513 , A61P1/08 , A61P3/08 , A61P9/08 , A61P13/02 , A61P21/02 , A61P21/04 , A61P25/00 , A61P25/06 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/34 , A61P25/36 , A61P27/02 , A61P29/02 , A61P43/00 , C07D243/12 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/10 , C07D405/04 , C07D405/06 , C07D409/04 , C07D409/08 , C07D409/14 , C07D413/10 , C07D417/02 , C07D417/04 , C07D417/06 , C07D417/10 , C07D417/14
Abstract: The present invention is a compound of formula wherein X is an ethynediyl group, R 1 , R 2 and R 3 are as defined in the specification.
-
公开(公告)号：SK8402003A3
公开(公告)日：2004-04-06
申请号：SK8402003
申请日：2001-11-26
Applicant: HOFFMANN LA ROCHE
Inventor： MUTEL VINCENT , PETERS JENS-UWE , WICHMANN JUERGEN
IPC: C07D233/64 , A61K31/4045 , A61K31/415 , A61K31/4164 , A61K31/4174 , A61K31/4178 , A61K31/4245 , A61K31/437 , A61K31/4985 , A61P1/08 , A61P9/02 , A61P9/10 , A61P13/02 , A61P21/02 , A61P25/00 , A61P25/04 , A61P25/06 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/34 , A61P25/36 , A61P31/18 , A61P43/00 , C07D209/14 , C07D209/16 , C07D231/12 , C07D233/54 , C07D233/58 , C07D233/68 , C07D233/90 , C07D233/92 , C07D233/94 , C07D403/06 , C07D403/10 , C07D413/04 , C07D491/147 , C07D495/14 , C07D498/04 , C07D513/14
Abstract: This invention relates to a compound and the use of the compound of the formula wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description, A signifies -CH-CH- or -C≡C-; and B signifies wherein R 6 to R 26 , X and Y are as defined in the specification or a pharmaceutically acceptable salt thereof, for use in pharmaceutical compositions for the treatment or prevention of mGluR5 receptor mediated disorders.
-
Patent Agency Ranking46.发明专利
公开(公告)号：GB2341179B
公开(公告)日：2004-02-18
申请号：GB9920579
申请日：1999-08-31
Applicant: HOFFMANN LA ROCHE
Inventor： ADAM GEO , HUGUENIN-VIRCHAUX PHILIPPE NIC , MUTEL VINCENT , STADLER HEINZ , WOLTERING THOMAS JOHANNES
IPC: A61K31/00 , A61K31/196 , A61P25/00 , A61P25/18 , C07C227/16 , C07C227/32 , C07C229/50 , C07C247/14
-
公开(公告)号：DE60006618D1
公开(公告)日：2003-12-24
申请号：DE60006618
申请日：2000-07-27
Applicant: HOFFMANN LA ROCHE
Inventor： ADAM GEO , BINGGELI ALFRED , MAERKI HANS-PETER , MUTEL VINCENT , WILHELM MAURICE , WOSTL WOLFGANG
IPC: C07D223/16 , A61K31/55 , A61P1/08 , A61P3/08 , A61P9/04 , A61P9/10 , A61P13/10 , A61P21/02 , A61P25/06 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P25/34 , A61P27/02 , A61P43/00 , C07D223/04 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D487/04 , C07D521/00 , C07F7/18 , G01N33/50
Abstract: The present invention is concerned with 1,2,4,5-tetrahydro-benzo[d]azepin derivatives as well as with their pharmaceutically acceptable salts in their racemic and optically active form, which compounds are antagonists at metabotropic glutamate receptors and therefore useful for the treatment of diseases related to these receptors.
-
公开(公告)号：NO20034576A
公开(公告)日：2003-11-12
申请号：NO20034576
申请日：2003-10-10
Applicant: HOFFMANN LA ROCHE
Inventor： WICHMANN JUERGEN , ADAM GEO , GOETSCHI ERWIN , MUTEL VINCENT , WOLTERING THOMAS JOHANNES
IPC: C07D243/12 , A61K31/551 , A61K31/5513 , A61P25/00 , A61P25/18 , A61P25/28 , A61P43/00 , C07D401/04 , C07D403/04 , C07D403/10 , C07D403/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14 , C07D243/14
CPC classification number: C07D401/04 , C07D403/10 , C07D403/14 , C07D417/10
-
公开(公告)号：AR032379A1
公开(公告)日：2003-11-05
申请号：ARP010105926
申请日：2001-12-20
Applicant: HOFFMANN LA ROCHE
Inventor： BINGGELI ALFRED , MAERKI HANS-PETER , MUTEL VINCENT , WILHELM MAURICE , WOSTL WOLFGANG
IPC: A61K31/495 , A61K31/53 , A61K31/55 , A61P1/08 , A61P9/10 , A61P13/02 , A61P19/00 , A61P21/00 , A61P21/04 , A61P25/00 , A61P25/04 , A61P25/06 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/36 , A61P27/02 , A61P43/00 , C07D403/04 , C07D495/04
Abstract: Compuestos de la formula general (1), en la cual: R1 significa hidrogeno, alquilo inferior, alquenilo inferior o fenilo no sustituido o fenilo sustituido en posicion meta o para con uno o más sustituyentes seleccionados entre el grupo que consiste en alquilo inferior, alcoxi inferior o halogeno, o está ausente, si X es -N= o =N-; R2 significa hidrogeno, alquilo inferior, alquenilo inferior, =O, -S-alquilo inferior, -SO2-alquilo inferior, o -OR, -O(CHR)m+1-OR, -NR2, -NH-NR2, -N(R)(CHR)m+1-OR, -N(R)(CHR)m-piridino, -N(R)(CHR)n-cicloalquilo C3-6, -N(R)(CHR)m(CR2)-NR2 o -N(R)(CHR)m+1-NH-C(O)-O-alquilo inferior; m es 1, 2, 3, 4, 5 o 6; n es 0, 1, 2, 3, 4 o 5; R significa hidrogeno, alquilo inferior o alquenilo inferior, independientemente uno de otro, si está presente más de un R; X significa -N=, =N-, >C= o =C
-
公开(公告)号：BR0115871A
公开(公告)日：2003-10-28
申请号：BR0115871
申请日：2001-11-26
Applicant: HOFFMANN LA ROCHE
Inventor： MUTEL VINCENT , PETERS JENS-UWE , WICHMANN JUERGEN
IPC: C07D233/64 , A61K31/4045 , A61K31/415 , A61K31/4164 , A61K31/4174 , A61K31/4178 , A61K31/4245 , A61K31/437 , A61K31/4985 , A61P1/08 , A61P9/02 , A61P9/10 , A61P13/02 , A61P21/02 , A61P25/00 , A61P25/04 , A61P25/06 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/34 , A61P25/36 , A61P31/18 , A61P43/00 , C07D209/14 , C07D209/16 , C07D231/12 , C07D233/54 , C07D233/58 , C07D233/68 , C07D233/90 , C07D233/92 , C07D233/94 , C07D403/06 , C07D403/10 , C07D413/04 , C07D491/147 , C07D495/14 , C07D498/04 , C07D513/14
Abstract: This invention relates to a compound and the use of the compound of the formula wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description, A signifies -CH-CH- or -C≡C-; and B signifies wherein R 6 to R 26 , X and Y are as defined in the specification or a pharmaceutically acceptable salt thereof, for use in pharmaceutical compositions for the treatment or prevention of mGluR5 receptor mediated disorders.
-
-
-
-
-
-
-
-
-
Search Results
480
records
(took 0.027 seconds)
